EN DE
Watch Vineet Laboratories Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vineet Laboratories Limited (VINEETLAB) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Vineet Laboratories Limited stock ₹25.30, price ₹37.52, that is 32.6% below the price, quality 30 out of 100. Rating: overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Basic Materials IN · ISIN INE505Y01010

VL Vineet Laboratories Limited logo Thin data Nov 15, 2026

Vineet Laboratories Limited

VINEETLAB · NSE

Expensive (fair value 33% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +41% vs. a year ago. 
Thin margins · 5.6% net margin (TTM) 
Mixed vs. peers (6/12) 
Fair value ₹25.30 · Overvalued 
Quality 30/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −24.6 %/yr in INR) 
Negative free cash flow 
Narrow moat 32/100
Thin data 
⟳ Cyclical⚠ Dilution
Watch Vineet Laboratories Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹112.34 ₹27.01 Fair Value ₹25.30 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range ₹27.01 – ₹112.34 · fair‑value band ₹21.09 – ₹32.55 · the ₹37.52 price screens above the ₹25.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Vineet Laboratories in your weekly email

Every Wednesday you see whether Vineet Laboratories is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India.

Show moreShow less

The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates.

It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde.

The company was incorporated in 2016 and is based in Hyderabad, India.

Stock analysis

Vineet Laboratories Limited (VINEETLAB) currently trades at ₹37.52, while our model-based Fair Value estimate is ₹25.30, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ₹31.37 per share, and 0 of the 13 models we run sit above the ₹37.52 price.

Bear case: the Growth Earnings group reads lowest at ₹7.50, and 13 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: ₹21.09 (bear) to ₹32.55 (bull), the price of ₹37.52 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 30/100 (below-average quality), in the Basic Materials sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Vineet Laboratories Limited reported revenue of ₹594M in FY2026 versus ₹1.9B in FY2022, a compound −25.3%/yr. Reported net income was ₹11.1M in FY2026, compounding −36.0%/yr from FY2022.

Key figures

Market cap ₹720M (≈ $7.6M) Micro · P/E ratio 15.4 · P/S ratio 1.15 · EPS (TTM) ₹2.44 · Net margin 5.6% · Return on equity 3.7% · Return on assets (EBIT) 0.5% (5-year average) · Operating margin 13.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).

What moves the price

The share trades about 16% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Basic Materials peers we cover trades at −28% fair-value upside, at −33%, VINEETLAB screens richer than that median.

Fair Value models

Bear ₹21.09 Fair Value ₹25.30 Bull ₹32.55
Price ₹37.52 · Downside -32.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 8 months old). Earnings retained since then (₹1.54 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Owner Earnings ₹24.81 ₹31.37 ₹42.43 78
EPV ₹26.58 ₹29.77 ₹32.42 74
ROIC Compounder ₹26.58 ₹30.32 ₹34.08 72
All 13 models by family
DCF Models
Owner Earnings ₹24.81 ₹31.37 ₹42.43 78
Earnings-Based
Graham-Dodd ₹3.93 ₹4.81 ₹5.41 67
EPV ₹26.58 ₹29.77 ₹32.42 74
Multiples
P/E Multiple ₹7.37 ₹9.83 ₹12.29 63
P/S Multiple ₹7.37 ₹9.83 ₹12.29 58
P/B Multiple ₹22.97 ₹30.63 ₹38.29 55
EV/EBIT ₹18.44 ₹29.49 ₹40.54 64
EV/EBITDA ₹18.40 ₹29.44 ₹40.47 66
EV/Revenue ₹14.02 ₹26.34 ₹38.65 52
Asset-Based
NCAV (Graham) ₹6.75 ₹10.23 ₹12.79 54
Economic Profit
Residual Income ₹15.49 ₹15.67 ₹16.22 71
ROIC Compounder ₹26.58 ₹30.32 ₹34.08 72
Growth Earnings
Growth-Adj P/E ₹5.25 ₹7.50 ₹9.76 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 30/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 34
Debt, balance sheet and risk of trouble
Investment 78
Does it invest with discipline instead of growing at any price?
Low Volatility 65
How calm the share price moves, does not count
Price momentum 41
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 38
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 14/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−20.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−24.6%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.0%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−32.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−32.1%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 10%

VINEETLAB screens overvalued: fair value 33% below the price. Compare with BASF SE →

Compare Vineet Laboratories Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 361 stocks

Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −32.6% · Below median
Profitability
Return on equity (12 months) 3.7% · Below median
Return on assets 0.9% · Below median
Net margin (12 months) 5.6% · Above median
Operating margin (12 months) 13.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) 40.8% · Top 25%
Balance sheet
Debt / equity 0.22× · Above median

Valuation Multiplesvs Chemicals median · lower = cheaper

P/E (12 months) 15.4× · Cheaper than median
P/B 1.58× · Pricier than median
P/S (12 months) 1.15× · Cheaper than median
EV/EBITDA 6.1× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 11
FUTURE (revenue growth)100 · sector 73
PAST (return on equity)15 · sector 24
HEALTH (low debt)89 · sector 94
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Chemicals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
LG Chem, Ltd 051910 227,000 KRW 587,755 KRW +159% vs VINEETLAB
Dow Inc DOW $33.04 $41.88 +27% vs VINEETLAB
Hengli Petrochemical Co 600346 ¥16.40 ¥19.26 +17% vs VINEETLAB
Ningxia Baofeng Energy Group 600989 ¥20.64 ¥22.31 +8% vs VINEETLAB
BASF SE BAS €53.74 €38.46 −28% vs VINEETLAB
Zhejiang Juhua Co 600160 ¥30.41 ¥19.31 −37% vs VINEETLAB
Formosa Chemicals & Fibre Corporation 1326 69.80 TWD 35.56 TWD −49% vs VINEETLAB
Ganfeng Lithium Group 002460 ¥34.89 ¥15.80 −55% vs VINEETLAB
Rongsheng Petrochemical Co 002493 ¥11.40 ¥4.15 −64% vs VINEETLAB
Zangge Mining Company 000408 ¥63.66 ¥17.47 −73% vs VINEETLAB

Explore undervalued stocks

More undervalued Basic Materials stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vineet Laboratories Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vineet Laboratories Limited Fair Value". https://www.fairvalue-calculator.com/stock/VINEETLAB

Frequently asked questions

Is Vineet Laboratories Limited (VINEETLAB) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of ₹25.30 versus a price of ₹37.52, about 33% lower (overvalued).
What is the fair value of VINEETLAB?
Our model-based fair value for Vineet Laboratories Limited is ₹25.30 (as of Nov 15, 2026), built from audited fundamentals. The current price: ₹37.52.
What is the quality score of VINEETLAB?
Vineet Laboratories Limited has a Quality Score of 30/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vineet Laboratories Limited (VINEETLAB)?
Our model-based price target is the fair value of ₹25.30 (as of Nov 15, 2026) from 13 valuation models. Cautious scenario ₹21.09, optimistic scenario ₹32.55. It is a calculation from audited fundamentals, not an analyst target.
What is the Vineet Laboratories Limited stock forecast for 2026?
Our models put fair value at ₹25.30, about 33% lower versus a price of ₹37.52 (overvalued). Cautious scenario ₹21.09, optimistic scenario ₹32.55. The calculation is refreshed regularly with new filings.
What is the revenue of Vineet Laboratories Limited (VINEETLAB)?
Vineet Laboratories Limited reported trailing-twelve-month revenue of about ₹625M (latest available figure, as of Nov 15, 2026).
What is the intrinsic value of Vineet Laboratories Limited (VINEETLAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vineet Laboratories Limited it is ₹25.30 per share (as of Nov 15, 2026), against a price of ₹37.52. It is the blended result of 13 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Vineet Laboratories Limited stock overvalued or undervalued in 2026?
As of Nov 15, 2026, VINEETLAB trades above its calculated fair value: price ₹37.52, fair value ₹25.30, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VINEETLAB?
No. The price is what the market pays today (₹37.52); the fair value is what the company's own numbers justify (₹25.30). For Vineet Laboratories Limited the two are ₹12.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vineet Laboratories Limited worth?
The market values Vineet Laboratories Limited at about ₹720M (market capitalisation, as of Nov 15, 2026). Per share that is ₹37.52; our models calculate a fair value of ₹25.30 per share.
What do the bullish and bearish scenarios say about VINEETLAB?
Our models span a range for Vineet Laboratories Limited: cautious scenario ₹21.09, base ₹25.30, optimistic ₹32.55 per share (as of Nov 15, 2026, price ₹37.52). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VINEETLAB?
Vineet Laboratories Limited trades at a price-to-earnings ratio of 15.4 (as of Nov 15, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹25.30 is built from several models across several years. Other multiples: P/B 1.6, P/S 1.2, EV/EBITDA 6.1.
How solid is the balance sheet of Vineet Laboratories Limited (VINEETLAB)?
Balance-sheet figures for Vineet Laboratories Limited (as of Nov 15, 2026): return on equity 3.7%, debt of 0.22 per unit of equity. They feed the Quality Score of 30/100, which measures business quality independently of the share price.
How far is VINEETLAB from its 52-week high?
Vineet Laboratories Limited trades at ₹37.52, about 16% below its 52-week high of ₹44.62 and 29% above the low of ₹29.01 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of ₹25.30 is for.
Which stocks are comparable to Vineet Laboratories Limited?
From the same area (Basic Materials) we also value BASF SE, Dow Inc, Ningxia Baofeng Energy Group, Rongsheng Petrochemical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vineet Laboratories Limited stock attractive at the current price?
The data as of Nov 15, 2026: price ₹37.52, calculated fair value ₹25.30 (−33%), Quality Score 30/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VINEETLAB calculated?
We run Vineet Laboratories Limited through 13 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹25.30 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Vineet Laboratories Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vineet Laboratories Limited (VINEETLAB)?
The closing price on Nov 16, 2026 was ₹37.52. Our model-based fair value is ₹25.30, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vineet Laboratories Limited right now?
The price sits above even our optimistic bull case (₹32.55). The favourable scenario is already priced in. Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Vineet Laboratories Limited

How large is the market capitalisation of Vineet Laboratories Limited (VINEETLAB)?
The market capitalisation of Vineet Laboratories Limited is ₹720M (≈ $7.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vineet Laboratories Limited (VINEETLAB)?
The price-to-sales ratio of Vineet Laboratories Limited is 1.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vineet Laboratories Limited (VINEETLAB)?
Earnings per share at Vineet Laboratories Limited are ₹2.44 (price ÷ EPS = P/E 15.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vineet Laboratories Limited (VINEETLAB)?
The net margin of Vineet Laboratories Limited is 5.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vineet Laboratories Limited (VINEETLAB)?
The return on equity (ROE) of Vineet Laboratories Limited is 3.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vineet Laboratories Limited (VINEETLAB)?
On an EBIT basis the return on assets of Vineet Laboratories Limited is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vineet Laboratories Limited (VINEETLAB)?
The operating margin of Vineet Laboratories Limited is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vineet Laboratories Limited (VINEETLAB)?
Revenue at Vineet Laboratories Limited is growing 40.8% versus a year earlier (3y avg −34.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vineet Laboratories Limited (VINEETLAB)?
Earnings per share at Vineet Laboratories Limited are down 45.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vineet Laboratories Limited (VINEETLAB) generate?
The free cash flow of Vineet Laboratories Limited is −₹180M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vineet Laboratories Limited (VINEETLAB) carry?
The net debt of Vineet Laboratories Limited is ₹283M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Vineet Laboratories Limited in the live analysis

One click puts Vineet Laboratories Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.